162 Thoracic Oncology Tumor Board Conference (081222)

Dallas, TX US
August 12, 2022

The multidisciplinary approach, including the medical, surgical and radiation areas of cancer therapy, providing a forum for the comprehensive care of complex cases in the management of thoracic cancer patients.

Target Audience

Faculty, Fellows, Residents, particularly those involved in the treatment of thoracic cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

1.    Follow established guidelines for diagnosis of thoracic cancer patients
2.    Incorporate multidisciplinary aspects in the care of thoracic cancer patients
3.    Offer available clinical research protocols to thoracic cancer patients

 

Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
  • 1.00 Ethics
Course opens: 
08/12/2022
Course expires: 
08/12/2022
Event starts: 
08/12/2022 - 7:00am CDT
Event ends: 
08/12/2022 - 8:00am CDT
Cost:
$0.00
UT Southwestern Medical Center
5323 Harry Hines Blvd.
ND3.218
Dallas, TX 75390
United States

 

 

 

 

Asha Kandathil

has no relevant financial relationships to disclose at this time.
Course Director(s)

John Waters, M.D.

has a financial relationship (Grant Or Contract) with Novocure Corporation;.
has a financial relationship (Professional Services) with Gore;.
Moderator(s)

Kenneth Westover, MD, PhD, Associate Professor of Radiation Oncology and Biochemistry

has a financial relationship (Grant Or Contract) with Revolution Medicines;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Professional Services) with Vibliome Therapeutics;.
Speaker(s)

Kiran Batra

has no relevant financial relationships to disclose at this time.

Jonathan Dowell

has a financial relationship (Professional Services) with astra zeneca;.
has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Genentech;.

David Gerber, MD

has a financial relationship (Grant Or Contract) with Sagimet;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Grant Or Contract) with BerGenBio;.
has a financial relationship (Independent contractor) with Catalyst Therapeutics;.
has a financial relationship (Grant Or Contract) with Karyopharm;.
has a financial relationship (Stock) with Gilead;.
has a financial relationship (Independent contractor) with Regeneron;.

Randall Hughes, M.D, Professor of Internal Medicine

has no relevant financial relationships to disclose at this time.
has no relevant financial relationships to disclose at this time.

Puneeth Iyengar, MD, PhD

has a financial relationship (Professional Services) with AZ;.

Fernando Kay, MD, PhD

has no relevant financial relationships to disclose at this time.

Kemp Kernstine, MD PhD

has no relevant financial relationships to disclose at this time.

VISHAL KUKKAR, MD

has no relevant financial relationships to disclose at this time.

Scott Reznik, MD

has a financial relationship (Stock) with Onconano ;.

Jennifer Schopp, MD

has no relevant financial relationships to disclose at this time.

Jose Torrealba, MD, Associate Professor

has no relevant financial relationships to disclose at this time.

Kenneth Westover, MD, PhD, Associate Professor of Radiation Oncology and Biochemistry

has a financial relationship (Grant Or Contract) with Revolution Medicines;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Professional Services) with Vibliome Therapeutics;.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance
  • 1.00 Ethics
 
Status
Price
Title

Price

Cost:
$0.00
Please login or create an account to take this course.